In the prostate, estrogen receptor B (ERB), the preferred receptor for phytoestrogens, has features of a tumor suppressor. To investigate the mechanisms underlying the beneficial effects on prostate cancer of histone deacetylase inhibitor valproic acid (VPA) and phytoestrogen tectorigenin, we analyzed the expression of ERB after tectorigenin or VPA treatment. For further functional analysis, we knocked down ERB expression by RNA interference. LNCaP prostate cancer cells were treated with 5 mmol/L VPA or 100 Mmol/L tectorigenin and transfected with small interfering RNA (siRNA) against ERB. Control transfections were done with luciferase (LUC) siRNA. Expression of ERB was assessed by Western blot. mRNA expression was quantitated by real-time reverse transcription-PCR. Expression of ERB mRNA and protein markedly increased after VPA or tectorigenin treatment. When ERB was knocked down by siRNA, the expression of prostatederived Ets factor, prostate-specific antigen, prostate cancer -specific indicator gene DD3 PCA3 , insulin-like growth factor-1 receptor, the catalytic subunit of the telomerase, and ERA was up-regulated and the tectorigenin effects were abrogated. ERB levels were diminished in prostate cancer and loss of ERB was associated with proliferation. Here, we show that siRNA-mediated knockdown of ERB increases the expression of genes highly relevant to tumor cell proliferation. In addition, we show that one prominent result of treatment with VPA or tectorigenin is the up-regulation of ERB resulting in antiproliferative effects. Thus, these drugs, by restoring the regulatory function of ERB in tumor cells, could become useful in the intervention of prostate cancer. [Mol Cancer Ther 2007;6(10):2626 -33] 
Introduction
In Western societies, prostate cancer is the most common malignancy in men, whereas, obviously due to dietary influences, Asian men have much lower incidences of prostate cancer than their Western counterparts (1) . This protection against prostate cancer in Asian societies is attributed to weak dietary estrogens such as isoflavonoids, flavonoids, and lignans contained in vegetarian food (e.g., soy products). These estrogens of plant origin, termed phytoestrogens, have a considerable affinity to estrogen receptors and bind generally in favor of the h isoform of estrogen receptors (2) . The expression status of the estrogen receptors at the mRNA and protein levels has been investigated intensely, sometimes with conflicting results (3 -5) . Nevertheless, it is widely accepted that estrogen receptor h (ERh) adopts a regulatory role in estrogen signaling, mediating antiproliferative effects. ERh restrains the transcriptional and proliferative activation conducted by ERa (6) and also modulates androgen receptor signaling (7, 8) . ERa is predominantly expressed in the stroma of the prostate and thus mediates effects via paracrine pathways. ERh is the estrogen receptor in prostate epithelium and shows decreased expression in prostate cancer. Many authors agree that ERh exerts a protective effect against aberrant cell proliferation and carcinogenesis (9 -12) . Each of the prostate cancer cell lines LNCaP, PC-3, and DU-145, according to Lau et al. (13) , expresses ERh, whereas only PC-3 cells express ERa. However, Linja et al. (5) found low mRNA expression of ERa in all three cell lines and reported detectable levels of ERh. Similar features for LNCaP cells were found by Ito et al. (3) . Loss of ERh expression at both the transcriptional and translational levels occurs during prostatic carcinogenesis and tumor progression, albeit metastatic prostate cancer cells may regain ERh expression (4, 9, 10, 14) . In a recent population-based prospective study on Japanese men, Kurahashi et al. (15) observed a dose-dependent decrease in the risk of localized prostate cancer with consumption of soy isoflavones. However, they also found that the effects of isoflavones differed by stage of prostate carcinoma, which became evident in an increased risk for advanced prostate cancer associated with one of the soy products investigated. As one explanation for this surprising effect, the authors suggest the protective role of ERh, which is partially or completely lost in cancers with higher metastatic potential (15) . The antiproliferative, anti-invasive, and proapoptotic properties of ERh indeed have been associated with the function of a tumor suppressor (16) and, therefore, the restoration of ERh, which is lost during carcinogenesis due to gene silencing, is a desirable goal for prostate cancer therapy. Gene silencing and consequent aberrantly repressed gene expression in cancers due to epigenetic events (i.e., DNA methylation and histone deacetylation) can be reversed by several drugs, which might represent therapy approaches for prostate cancer (17, 18) . Recently, we introduced the therapeutic potential of valproic acid (VPA) for prostate cancer, which featured inhibition of histone deacetylase activity in LNCaP prostate cells (19) . VPA is an established anticonvulsant that has been characterized as an inhibitor of histone deacetylases (20) . As a consequence of VPAinduced histone deacetylase inhibition, we found increased expression of insulin-like growth factor (IGF) -binding protein 3 and tissue inhibitor of matrix metalloproteinases-3 in LNCaP prostate cancer cells. In another study, we showed that phytoestrogens such as the isoflavone tectorigenin can also rectify the abnormal expression of key elements responsible for the malignancy of prostate cancer (21) . Tectorigenin binds to both estrogen receptors, ERa and ERh, albeit with a higher affinity for ERh, and has selective estrogen receptor modulator activities (22) . Here, we report that a common denominator in the beneficial effects from these drugs is the increase of ERh expression. Recently, the molecular mechanisms underlying ERh actions in androgen-independent DU-145 (23) and androgen-responsive LNCaP (24) prostate cancer cells have been investigated using small interfering RNA (siRNA). To further elucidate ERh functions and phytoestrogen effects, we conducted knockdown analyses by siRNA-mediated silencing of ERh expression. This study revealed the capacities of the phytoestrogen tectorigenin as well as of the histone deacetylase inhibitor VPA to reestablish ERh expression. siRNA-mediated silencing of ERh reversed the effects of both compounds and abrogated the beneficial effects elicited by tectorigenin.
Materials and Methods
Cell Culture Human prostate cancer cell lines PC-3 and LNCaP between passages 30 and 40 were grown in phenol redfree RPMI 1640 (PAN-Systems GmbH) containing 10% FCS (PAA), 1% L-glutamine, 2% amino acid solution, and 1% penicillin-streptomycin. For VPA and TG stimulation, cells were suspended in 5-mL medium at f60% confluence using 50-mL culture flasks and allowed to seed overnight. To exclude para-estrogen effects, for VPA and TG stimulation, cells were grown in DMEM. For siRNA transfection, LNCaP cells were grown in RPMI medium. Tectorigenin (Girindus) was dissolved in DMSO as a 1,000Â stock solution and added at a final concentration of 10, 50, and 100 Amol/L, respectively, to DMEM. An equivalent volume of DMSO was added to control flasks. Cells were incubated for 24 h at 37jC and 5% CO 2 in a humidified incubator. Na-valproat (Sigma) was dissolved in DMEM at a final concentration of 1, 5, or 10 mmol/L, respectively. After 24 h incubation, cells were harvested for RNA and protein extraction or used for cell viability assay. Treatment of LNCaP cells with the antiestrogen ICI 182,780 (100 nmol/L) was carried out for 24 h with ethanol as solvent.
siRNA Transfection Cells were plated in six-well plates 24 h before transfection with two different siRNA oligonucleotides against ERh (Stealth siRNA duplex oligoribonucleotides, Invitrogen). In control transfections, we used LUC siRNA against the luciferase gene (Eurogentec). We used Oligofectamine reagent (Invitrogen) and Opti-MEM (Invitrogen) according to the manufacturers' recommendations. The day before transfection, cells were seeded in six-well plates at a density of 8 Â Western Blots Protein expression was assessed by Western blot analysis with 3 Ag/mL mouse anti-ERh (Genetex), mouse anti-ERa (Santa Cruz Biotechnology, Inc.), and mouse anti -a-tubulin (Sigma-Aldrich) monoclonal antibodies. After 68 h of incubation, transfected LNCaP cells were homogenized with lysis buffer containing 150 mmol/L NaCl, 1 mmol/L EDTA, 50 mmol/L Tris-HCl (pH 7.4), 1% NP40, 0.25% sodium deoxycholate, 1 mmol/L phenylmethylsulfonyl fluoride, 1 Ag/mL aprotinin, 1 Ag/mL leupeptin, 1 Ag/mL pepstatin A, 1 mmol/L Na 3 VO 4 , and 1 mmol/L NaF. After centrifugation, cell lysates were boiled and denatured in sample buffer containing SDS and DTT (Invitrogen). NuPAGE 4% to 12% Bis-Tris precast gel and MES buffer (Invitrogen) were used for electrophoresis. After electrotransfer onto polyvinylidene difluoride membrane (GE Healthcare), protein-bound membrane was hybridized with the above-mentioned antibodies. For visualization, we used horseradish peroxidase -coupled secondary antibodies (Dianova) and the ECL Plus kit (GE Healthcare).
RNA Extraction and cDNA Synthesis Cells were detached with trypsin and washed with PBS, and then total cellular RNA was extracted with RNeasy Mini Kit (Qiagen) from pelleted LNCaP cells. The integrity and quantity of isolated RNA was measured by Agilent Bioanalyzer 2100 with a RNA 6000 Nano LabChip-Kit (Agilent Technologies). Isolated, total cellular RNA was reverse transcribed with Omniscript RT Kit (Qiagen).
Real-time ReverseTranscription-PCR cDNA resulting from reverse transcription was used for mRNA quantification by reverse transcription-PCR (iCycler, Bio-Rad). For all primer sets, a 20-AL PCR reaction, using a SYBR Green RT-PCR Kit (Eurogentec), was subjected to 2 min 50jC, 10 min 95jC, then 40 cycles of 15 s 95jC and 1 min for individual primers at annealing temperature, followed by a melting curve analysis to prove specificity of the PCR. In all experiments, housekeeping gene acidic ribosomal protein (ARP) served as an internal control. Quantitative PCR was done as previously published (19) . Primers for ERh were the Quantitect Primer Assay Hs_ESR2_1_SG (Qiagen). ERa sequence was taken from ref. 25 and prostate-derived Ets factor (PDEF), prostate-specific antigen (PSA), prostate cancerspecific indicator gene DD3 PCA3 (DD3), porphobilinogen deaminase (PBGD), and the catalytic subunit of the telomerase (hTERT) were used as previously described (21) . Primers for the housekeeping gene ARP were forward primer, 5 ¶-CGACCTGGAAGTCCAACTAC-3 ¶, and reverse primer, 5 ¶-ATCTGCTGCATCTGCTTG-3 ¶.
Cell Viability, Proliferation, and Cytotoxicity Assays For VPA and TG treatments (24 h; 5,000 cells per well), a colorimetric bromodeoxyuridine test (Roche Diagnostics GmbH) was done according to the manufacturer's instructions. For siRNA transfections, cells were transfected as described and incubated for 62 h in 96-well plates; cell viability was measured with an Alamar Blue assay (Biosource).
Statistical Analyses Statistical calculations, EC 50 values, mean F SD, and P values were carried out with GraphPad Prism software version 2.0 and calculated using the unpaired nonparametric t test at 95% confidence interval and using MannWhitney U tests with P < 0.05 considered statistically significant.
Results

VPA as well as Tectorigenin Treatment Causes an Increase of ERB Expression
In an attempt to identify the initiation of the antiproliferative and proapoptotic effects accompanied by changes in gene expression observed with VPA and tectorigenin treatments, we quantitated ERh expression in prostate cancer cells. As shown in Fig. 1A , VPA or tectorigenin evoked marked increases of ERh mRNA expression in LNCaP prostate cancer cells. In contrast, the housekeeping gene ARP did not respond to such treatments (Fig. 1B) . In concordance with elevated ERh mRNA expression, protein expression was also significantly increased, whereas the expression of the housekeeping gene a-tubulin remained constant (Fig. 1C) . VPA or tectorigenin treatment had an opposite effect on ERa expression. As shown in Fig. 1D , ERa expression was down-regulated in the same experiments where ERh had been up-regulated by these drugs.
Treatment of LNCaP cells with various concentrations of VPA also caused a marked decrease of cell proliferation with a maximum effect at 5 mmol/L, whereas tectorigenin decreased cell proliferation significantly at concentrations >50 Amol/L (Fig. 1E) . A combination of 1 mmol/L VPA pretreatment for 24 h and then tectorigenin (10 - Table  S1A) . 4 In an attempt to selectively knock down ERh expression without apparent side effects, we applied RNA interference with siRNA oligos targeted at ERh expression. We used two different siRNA sequences against ERh, which both eliminated ERh expression to a similar extent in a range of 10% to 30% residual expression (data not shown). The following experiments were done with ERh siRNA 2 oligos itemized in Material and Methods. As evident in Fig. 2A and B, transfection of LNCaP cells with ERh siRNA 2 oligos caused a marked knockdown of ERh expression at the mRNA and protein levels. The ERh knockdown with siRNA had no immediate effects on tumor cell viability (Fig. 2C) . In addition, off-target effects from siRNA 2 oligos could be excluded because ERa, with a sequence very homologous to ERh, was not knocked down by these siRNA oligos (Fig. 3F and Fig. 3H) .
Changes of Gene Expression Induced by VPA or Tectorigenin Are Reversed by ERB Knockdown
The knockdown of ERh expression with siRNA caused an altered expression status for several genes. These alterations deflect into the opposite direction as those following VPA or tectorigenin treatment. Hence, PDEF, PSA, DD3, IGF-I receptor, and hTERT, the expressions of which were shown to be down-regulated after VPA or tectorigenin treatment, were up-regulated by ERh knockdown ( Fig. 3A -E) . Furthermore, ERh knockdown induced the expression of ERa, which is normally repressed in LNCaP cells (Fig. 3F) .
Thus, siRNA-mediated knockdown of ERh caused an opposite effect compared with VPA or tectorigenin treatment where, concomitant with increased ERh expression, the ERa expression was down-regulated (Fig. 1D) . Housekeeping gene ARP ( Fig. 2A) did not change its expression status following such treatments. The same was true for the low-expressed housekeeping gene PBGD (Fig. 1G) .
ERB Knockdown Abolished the Effects of TectorigeninTreatment
Two prominent effects of tectorigenin treatment in LNCaP cells are concomitant PDEF and PSA decreases. 4 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). These effects were markedly abolished when LNCaP cells were deprived of ERh by a preceding siRNA-mediated knockdown of ERh expression. As evident from Fig. 4 , the usual decrease of PDEF and PSA caused by tectorigenin treatment was considerably impaired when ERh had been knocked down before (right columns). However, in siLUC control -transfected cells, the tectorigenin effect was still detectable (left columns ). Such an effect of an ERh abolishment could not be shown for ICI pretreatment because the expression of PDEF and PSA was decreased by ICI treatment per se (Supplementary Table S1B ). 4 
Discussion
In the present study, we introduced the potential of histone deacetylase inhibitors and phytoestrogens to up-regulate ERh expression in prostate cancer cells and showed the consequences of a knockdown of this receptor. ERh plays a pivotal role in carcinogenesis of the prostate and a decreased expression is associated with progression into pathologic stages of the disease. Restoring ERh by adenoviral delivery in ER-negative DU-145 cells caused decreased invasiveness and growth and increased apoptosis of the prostate cancer cells, which reveals features of a tumor suppressor for ERh (16) . This became evident in the most recent study of Kurahashi et al. (15) with a seemingly contradictory conclusion. They found that intake of soyderived isoflavones decreased the risk of localized prostate cancer but increased the risk of an advanced disease. As an explanation, it might suffice that in the latter, ERh expression is lost and cannot convey the protection from phytoestrogens. Therefore, an intrinsic potential for an increase of ERh expression might restore the therapeutic potential of phytoestrogens.
Epigenetic silencing, the abnormal repression of gene expression during cancer development, is generally caused by two distinct events: CpG island hypermethylation and histone hypoacetylation. In this study, we showed that the histone deacetylase inhibitor VPA caused reexpression of ERh; moreover, the sole treatment of LNCaP cells with the phytoestrogen tectorigenin sufficed to restore ERh expression. Although the ERh promoter region shows a typical CpG island (18), we showed that inhibition of histone deacetylases alone yielded a considerable restoration of ERh expression. This fact will ease the therapeutic application of ERh up-regulation in prostate cancer, especially because VPA has a long-standing reputation as an anticonvulsant with manageable side effects. The use of VPA in rather high concentrations (e.g., 5 mmol/L) is common for in vitro studies to evoke immediate effects. In humans, VPA is used in daily doses as high as 50 mg/kg (26) . In previous studies, we showed that histone deacetylase activity is reduced significantly with VPA concentrations of 1 and 5 mmol/L and that trichostatin A, an established histone deacetylase inhibitor, caused similar effects in LNCaP cells (19) . This study also revealed an induction of apoptosis due to treatment of LNCaP with VPA, indicated by a strong caspase-3 activity and DNA fragmentation. In terms of therapeutic applicability, the phytoestrogen tectorigenin is promising. Pure phytoestrogens are currently under investigation in clinical trials with safe doses of the phytoestrogen silibinin of 4 g/d (27) . We used a phytoestrogen extract from Belamcanda chinensis, in which tectorigenin is a major component, in mice in doses of 1.5 g/kg of body weight without adverse effects for the test animals (21) . In case of VPA, the up-regulation of ERh expression most probably is due to a reversion of gene silencing by the histone deacetylase inhibitory properties of this drug. Because tectorigenin has selective estrogen receptor modulator activities, one explanation for the mechanism behind the up-regulation of ERh seen here might be a feedback loop, which involves binding, modulation, and elevated transcription of this estrogen receptor. We have several lines of evidence that the phytoestrogen tectorigenin exerts its effects via ERh and not via ERa or the mutant androgen receptor in LNCaP cells. We showed that tectorigenin has a strong affinity to both estrogen receptors with a preference for ERh (22) , and Bektic et al. (7) showed a very low affinity for isoflavones of the mutant androgen receptor. Furthermore, estradiol, activating the mutant androgen receptor in LNCaP, caused increased PSA expression, which is not seen for tectorigenin. In addition, PC-3 prostate cancer cells, which do not express an androgen receptor but the coactivator PDEF, showed a down-regulation of PDEF expression similar to LNCaP cells on tectorigenin treatment in the absence of an androgen receptor (data not shown).
Inhibition of histone deacetylase activity by VPA caused a decrease of tumor cell proliferation, decreased expression of PDEF and PSA, and increased expression of IGF-binding protein 3 and tissue inhibitor of metalloproteinase-3 in LNCaP cells (19) . Such effects also occurred when LNCaP cells were treated with the phytoestrogen tectorigenin. In addition, tectorigenin diminished the expression of androgen receptor, DD3, IGF-1 receptor, and hTERT (21) . In the present study, we found that a common denominator in both treatments is the up-regulation of ERh expression. To further clarify the succession and molecular mechanism behind these events, we tried to elucidate the role of ERh herein by blocking the remaining ERh function of LNCaP cells. We failed to apply the antiestrogen ICI 182,780 in this capacity. Because of its marked antiproliferative and proapoptotic effects (13) , ICI 182,780 obviously does not qualify for pretreatment studies and subsequent experiments in the same cell culture.
Pretreatment with RNA interference to eliminate ERh has one advantage over pretreatment with a conventional drug to this end: experiment and control experiment share the same strain exposure caused by such pretreatments. The only difference between experiment and control is the sequence of the siRNA (i.e., siERh or siLUC, respectively). Therefore, we applied RNAi to solely exclude ERh expression and carried out functional analysis by means of siRNA-mediated silencing of ERh. ERh-specific RNA interference decreased expression of ERh mRNA and protein without immediate alteration of cell viability. Silencing of ERh by siRNA indeed impaired the effect of tectorigenin treatment as indicated by the expression of PDEF and PSA. siRNA silencing of ERh without tectorigenin induced ERa expression and markedly increased the expression of PDEF, PSA, DD3, IGF-1 receptor, and hTERT. Thus, decreased ERh expression is accompanied by the increase of key elements in carcinogenesis, whereas ERh restoration caused a decrease of these functions. In addition, ERh down-regulation abolished the beneficial effects seen with tectorigenin treatment. The relevance of these factors to prostate cancer, which obviously respond to the level of ERh, is well characterized in the literature. PDEF as a coactivator of the androgen receptor that regulates the activity of the PSA promoter is a strong indicator for cancer cell malignancy and shows a better tumor association than Her2/neu, CA-125, Bcl-2, survivin, or telomerase (28, 29) .
DD3 is a prostate-specific gene that is overexpressed in more than 95% of prostate cancer. This gene is used as a marker for prostate cancer and is considered for interventions targeting exclusively cells of malignant transformation (30) . Deregulated vascular endothelial growth factor, hTERT, or components of the IGF-axis have a welldefined effect on many cancers including prostate cancer. hTERT activity is known to be regulated by estrogen receptor signaling (31) . Finally, the IGF-1 receptor plays a pivotal role in ligand-independent androgen receptor activation in hormone-refractory disease, is overexpressed in prostate cancer, and persists in the metastatic disease (32), and ERa has proproliferative features that are restrained by ERh (6) .
In conclusion, we showed that drugs with very different chemistries, such as short fatty acid acting as a histone deacetylase inhibitor as well as phytoestrogen isoflavones, cause an up-regulation of ERh expression and therefore transform prostate cancer cells into a less malignant phenotype. Our application of RNA interference added more insights into the role of ERh in phytoestrogen treatment of prostate cancer cells and further characterized the function of ERh in prostate cancer. Future examinations of histone deacetylase inhibitors in combination with phytoestrogens are warranted.
